Abstract
From 1997 through 1999, the prevalence of the zidovudine resistance mutation T215Y was 9.7% among pregnant women, and the human immunodeficiency virus type 1 (HIV-1) load in those with resistant virus was higher than that measured in women with wild-type HIV-1. All mutations were noted in women with zidovudine experience, which suggests that monotherapy may not be adequate prophylaxis for vertical transmission of HIV-1 infection in the current era.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
Cohort Studies
-
Drug Resistance, Microbial / genetics
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology
-
HIV Infections / prevention & control
-
HIV Infections / virology*
-
HIV Reverse Transcriptase / genetics*
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
HIV-1 / physiology
-
Humans
-
Infant, Newborn
-
Infectious Disease Transmission, Vertical / prevention & control
-
Mutation
-
New York / epidemiology
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy
-
Pregnancy Complications, Infectious / epidemiology
-
Pregnancy Complications, Infectious / virology*
-
Prevalence
-
RNA, Viral / blood
-
Reverse Transcriptase Inhibitors / pharmacology
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Viral Load
-
Zidovudine / pharmacology*
-
Zidovudine / therapeutic use
Substances
-
Anti-HIV Agents
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Zidovudine
-
HIV Reverse Transcriptase